MedTrace Logo

A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.

NCT02174861 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 609

Last updated 2022-10-12

Study results available
· View outcomes & findings →

Summary

To assess the long-term safety and efficacy of erenumab.

Conditions

  • Treatment for Prevention of Chronic Migraine

Interventions

DRUG

Erenumab

Administered by subcutaneous injection once a month

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2017-05-26
Completion
2017-05-26

Countries

  • United States
  • Canada
  • Czechia
  • Denmark
  • Finland
  • Germany
  • Norway
  • Poland
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02174861 on ClinicalTrials.gov